BridgeMD
New treatment option for Physical Therapy
Official title Reflexo Therapy for Gestational Diabetes Mellitus
ClinicalTrials.gov ID: NCT06976164
What this study is testing
- What it's testing
- The purpose of this study will be to detect the effects of Reflexo therapy of sole on GDM.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 35, women only
You may be able to join if
- They were maternally aged between 20 and 35 years.
- The gestational age ranged from between 24 and 36 weeks.
- Their BMI didn't exceed 30 kg/m2.
- A singleton live fetus and not under stressful event.
You likely can't join if
- They had high-risk pregnancies.
- Bad obstetric situations.
- Diseases that could interfere with participation.
- Smoking.
- Oral sedative administration.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.